Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SELLAS Life Sciences Group ( (SLS) ) just unveiled an update.
Subsequent to December 31, 2025, SELLAS Life Sciences Group, a biopharmaceutical company, received approximately $26.5 million in cash proceeds from the exercise of common stock warrants, strengthening its capital position and potentially extending its operating runway. As of January 7, 2026, the company had 170,282,026 shares of common stock outstanding, reflecting a meaningful increase in share count that may have implications for existing shareholders’ ownership dilution and future capital markets activity.
The most recent analyst rating on (SLS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on SELLAS Life Sciences Group stock, see the SLS Stock Forecast page.
Spark’s Take on SLS Stock
According to Spark, TipRanks’ AI Analyst, SLS is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, ongoing losses, and persistent cash burn) and limited valuation support due to negative earnings and no dividend. These are partially offset by strong technical momentum with price above key moving averages and a positive MACD, though near-overbought indicators add pullback risk.
To see Spark’s full report on SLS stock, click here.
More about SELLAS Life Sciences Group
Average Trading Volume: 7,196,483
Technical Sentiment Signal: Buy
Current Market Cap: $584M
For a thorough assessment of SLS stock, go to TipRanks’ Stock Analysis page.